Cargando…
Erratum: Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: Case report and mini-review of the literature
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084836/ https://www.ncbi.nlm.nih.gov/pubmed/37051212 http://dx.doi.org/10.3389/fmed.2023.1186494 |
Ejemplares similares
-
Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature
por: Buetler, Vanessa Alexandra, et al.
Publicado: (2022) -
Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
por: Güney, Tekin, et al.
Publicado: (2022) -
Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
por: Ruhe, Johannes, et al.
Publicado: (2021) -
Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient
por: Yoshida, Kikuaki, et al.
Publicado: (2021) -
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
por: Waqar, Syed Hamza Bin, et al.
Publicado: (2021)